Medigene AG
MDGEF · OTC
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.05 | 0.05 | 0.00 |
| FCF Yield | -13.69% | -12.07% | -9.57% | -6.66% |
| EV / EBITDA | -7.16 | -6.18 | -10.97 | 4.16 |
| Quality | ||||
| ROIC | -28.60% | -40.83% | -17.90% | -6.10% |
| Gross Margin | 82.73% | 75.72% | 69.91% | 80.41% |
| Cash Conversion Ratio | 1.05 | 0.77 | 1.15 | 0.24 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.12% | 27.26% | 32.84% | 39.84% |
| Free Cash Flow Growth | 0.19% | 11.64% | -38.47% | -135.44% |
| Safety | ||||
| Net Debt / EBITDA | 1.93 | 0.75 | 2.10 | -1.06 |
| Interest Coverage | 0.00 | -16.01 | 0.00 | -5.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -37.82 | -29.83 | -47.66 | 2.03 |